Table 2.
Overview of tumour stage, diagnosis duration, Karnofsky performance index, haemoglobin and therapy.
| Study 1: Cancer group | Study 2: | BC | CRC | |
|---|---|---|---|---|
| Metastasis or generalised stage | ||||
| Yes | 35 (61.4%) | 2 | 3 | |
| No | 24 (38.6%) | Stage 1: | 3 | 0 |
| Stage 2: | 8 | 2 | ||
| Stage 3: | 4 | 18 | ||
| Missing: | 0 | 2 | ||
| Initial diagnosis (years) | Initial diagnosis (month) | |||
| Mean(SD) | 2.9 (3.1) | 1.3 (1.0) | 1.4 (0.5) | |
| Median | 2.0 | 1.0 | 1.0 | |
| Min/Max | 0/12 | 1/5 | 1/2 | |
| Karnofsky-lndex (%) | ||||
| Mean (SD) | 81.8(11.6) | 86.7(10.5) | 88.7 (9.2) | |
| Median | 90 | 90 | 90 | |
| Haemoglobin (gr/dl) | ||||
| Mean (SD) | 12.1 (1.84) | 13.0(1.28) | 13.7(6.8) | |
| Median | 12.5 | 13.2 | 12.65 | |
| Anemia (< 12) | 22 (38.5%) | 2(11.1%) | 9 (36.0%) | |
| Therapies received at the point of questioning | after first questioning | |||
| Operation because of cancer | ||||
| Yes | 39 (68.4%) | 14(82.3%) | 25(100%) | |
| Chemotherapy | ||||
| Yes | 31 (54.4%) | 17 (100%) | 25 (100%) | |
| Chemotherapy Scheme | ||||
| CMF + RAD | 2 | |||
| EC or EC + | 7 | |||
| RAD | ||||
| EC/CMF or | 3 | |||
| EC/CMF + | ||||
| RAD | ||||
| FEC or FEC + | 1 | |||
| RAD | ||||
| EC/Tac | 1 | |||
| Tac/other | 2 | |||
| 5FU (Mayo | 5 | |||
| mod/Ardatan) | ||||
| 5FU + RAD | 5 | |||
| FOLFOX | 12 | |||
| FOLFOX + | 1 | |||
| RAD | ||||
| OXALI mono or others | 2 | |||
| Radiotherapy | ||||
| Yes | 14 (24.6%) | 6 (35.2%) | 0(0) | |
| Antihormonal therapy | ||||
| Yes | 13 (22.8%) | 6 (35.2%) | 0(0) | |
| Mistletoe therapy | ||||
| Yes | 57 (100%) | 17 (100%) | 25 (100%) | |